Filing Flows

Filing Flows › Companies › Biodesix › Cash flow

Biodesix cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$7.8M in Q3 2026 · −$19.1M over twelve months

Operating cash flow−$7.2M
Capital spending−$555K
Free cash flow−$7.8M

Analysis

In Q3 2026, Biodesix generated −$7.2M of operating cash flow and spent $555K on capital projects, leaving free cash flow of −$7.8M. That is $1.2M more than in Q3 2025 (−$8.9M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$18.2M; the largest uses were operating cash flow ($18.2M), other financing ($1.7M), capital spending ($919K); besides operations, cash came from shares issued ($32.8M); the cash balance rose by $11.8M.

Operating cash flow was −$7.2M against net income of −$8.0M. The largest differences: payables −$1.5M, depreciation & amortization +$1.4M, stock-based pay +$852K.

Free cash flow

Biodesix: free cash flow by quarterBiodesix: free cash flow by quarter−$4.9MQ4 2024−$8.7MQ1 2025−$6.6MQ2 2025−$8.9MQ3 2025$692KQ4 2025−$10.2MQ1 2026−$1.8MQ2 2026−$7.8MQ3 2026
Operating cash flow less capital spending.
Biodesix: operating cash flow against capital spendingBiodesix: operating cash flow against capital spendingOperating cash flowCapital spending−$4.1M$839KQ4 2024−$8.6M$74KQ1 2025−$6.6M$51KQ2 2025−$8.9M$48KQ3 2025$778K$86KQ4 2025−$10.2M$81KQ1 2026−$1.6M$197KQ2 2026−$7.2M$555KQ3 2026
Latest (Q3 2026): Operating cash flow −$7.2M, Capital spending $555K.

Capital allocation, year by year

Biodesix: where the cash came from (up) and went (down), by fiscal yearBiodesix: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingFY2021: Operating cash flow −$28.2MFY2021: Net borrowing −$45.4MFY2021: Shares issued $17.1MFY2021: Capital spending −$2.2M$17.1MFY2021FY2022: Operating cash flow −$45.0MFY2022: Shares issued $59.8MFY2022: Capital spending −$3.3M$59.8MFY2022FY2023: Operating cash flow −$22.9MFY2023: Net borrowing −$49KFY2023: Shares issued $28.2MFY2023: Capital spending −$22.9M$28.2MFY2023FY2024: Operating cash flow −$48.6MFY2024: Net borrowing −$51KFY2024: Shares issued $55.6MFY2024: Capital spending −$3.2M$55.6MFY2024FY2025: Operating cash flow −$23.3MFY2025: Net borrowing −$21KFY2025: Shares issued $7.3MFY2025: Capital spending −$259K$7.3MFY2025
Over these 5 years operating cash flow totalled −$168M; the largest uses were operating cash flow ($168M) and net borrowing ($45.5M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$28.4M
Debt$50.0M
Net debt$21.6M
Cash runway18 months

Biodesix is burning cash: its operations consume cash, a free cash flow of −$19.1M a year at the current rate against $28.4M of cash and investments: a runway of about 18 months before any new financing.

Where the cash came from and went

Biodesix: sources (+) and uses (−) of cash, Q3 2026Biodesix: sources (+) and uses (−) of cash, Q3 2026Operating cash flow−$7.2MShares issued$6.6MCash drawn (+) / kept (−)$1.6MCapital spending−$555KOther financing−$385KOther investing−$45K
Biodesix: sources (+) and uses (−) of cash, TTM to Q3 2026Biodesix: sources (+) and uses (−) of cash, TTM to Q3 2026Shares issued$32.8MOperating cash flow−$18.2MCash drawn (+) / kept (−)−$11.8MOther financing−$1.7MCapital spending−$919KOther investing−$183KNet borrowing (+) / repaid (−)−$11K

From profit to cash

Biodesix: net income to operating cash flow, Q3 2026Biodesix: net income to operating cash flow, Q3 2026Net income−$8.0MDepreciation & amortization$1.4MStock-based pay$852KReceivables−$200KPayables−$1.5MDeferred revenue$127KPrepaid and other assets−$65KOperating cash flow−$7.2M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026−$7.2M−$555K—$6.6M$1.6M−$7.8M
Q2 2026−$1.6M−$197K−$1K$6.7M−$4.4M−$1.8M
Q1 2026−$10.2M−$81K−$5K$17.2M−$6.6M−$10.2M
Q4 2025$778K−$86K−$5K$2.3M−$2.4M$692K
Q3 2025−$8.9M−$48K−$4K—$4.1M−$8.9M
Q2 2025−$6.6M−$51K−$5K—−$3.1M−$6.6M
Q1 2025−$8.6M−$74K−$7K—$8.6M−$8.7M
Q4 2024−$4.1M−$839K−$13K$6K$5.2M−$4.9M

Biodesix: income statement and cash flow

Biodesix, Q3 2026: revenue $24.0M (+10% year over year), operating margin -25.4%. The chart follows the revenue to costs, profit and cash.

Biodesix: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.